Ranbaxy Laboratories is currently trading at Rs. 391.80, up by 13.40 points or 3.54% from its previous closing of Rs. 378.40 on the BSE.

The scrip opened at Rs. 378.00 and has touched a high and low of Rs. 393.00 and Rs. 368.30 respectively. So far 619956 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 578.30 on 04-Sep-2012 and a 52 week low of Rs. 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 417.60 and Rs. 320.00 respectively. The current market cap of the company is Rs. 16078.92 crore.

The promoters holding in the company stood at 63.51% while Institutions and Non-Institutions held 20.74% and 13.69% respectively.

Indicating a shift in its business strategy, Ranbaxy could withdraw from some global markets in the near future, while consolidating in others. The company has identified smaller markets such as Peru, which do not contribute significantly to profits, where it might shut shop in the near term. Besides, there are also directions from top management to avoid participating in domestic as well as international tenders with less than five per cent margin. This is part of the ongoing cost rationalisation process within the company. There is pressure to minimise cost and increase profitability.

The company has identified key regions to drive its future growth. In the Asia-Pacific region it will focus on Malaysia, Australia and New Zealand, Japan and China. However, the company is present in various other countries in the region such as Vietnam, Nepal, Oman, Sri Lanka, Hong Kong, Cambodia and Myanmar.  Similarly, in Africa, the company has identified South Africa, Nigeria, Egypt and Morocco as key for future growth. Ranbaxy is also present in other countries like Cameroon, Kenya, Ivory Coast, Mauritius and Zambia in Africa.

The company also plans to focus on some of the emerging markets that are expected to grow in the range of 12-15 per cent a year. These markets are anticipated to nearly double pharmaceutical spending in the next five years, adding $ 180 billion by 2016 and Ranbaxy is well placed to gain from the expansion in these markets.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×